Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib

J Clin Oncol. 2012 Mar 20;30(9):e109-11. doi: 10.1200/JCO.2011.39.0377. Epub 2012 Feb 13.

Authors

Dennis Cornfield¹, Usman Shah, Nicholas Cross, Courtney Bennett, Guoxian Sun

Affiliation

¹ Lehigh Valley Hospital, Allentown, PA, USA.

PMID: 22331939
DOI: 10.1200/JCO.2011.39.0377

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Gene Rearrangement*
Humans
Imatinib Mesylate
In Situ Hybridization, Fluorescence
Male
Middle Aged
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / genetics*
Philadelphia Chromosome*
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Receptor, Platelet-Derived Growth Factor beta / genetics*
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Receptor, Platelet-Derived Growth Factor beta